The Surgical Care Improvement Project (SCIP) is a national program undertaken to improve outcomes in surgery and, specifically, to reduce surgical site infections. 8 One of the core SCIP quality measures involves glycemic control after cardiac surgery. SCIP has benchmarked that 6:00 AM blood sugar levels on postoperative days (PODs) 1 and 2 be less than 200 mg/dL as the indicator of glycemic control after cardiac surgery. Compliance with these quality measures is publicly reported on the Centers for Medicare and Medicaid hospital website and is used to determine monetary reimbursement for participating hospitals. However, several studies have questioned the relevance of SCIP in directly leading to improved surgical outcomes. [9] [10] [11] [12] Furthermore, the relevance of a single SCIP glucose measurement in cardiac surgical patients already receiving a continuous insulin infusion (CII) targeted to achieve a serum glucose level of less than 180 mg/dL is unknown. This study was therefore undertaken to (1) determine the incidence of SCIP outliers in adults undergoing cardiac surgery and receiving a CII targeted to maintain perioperative serum glucose of less than 180 mg/dL, (2) identify the profile of patients in this cohort who are SCIP outliers, (3) determine whether SCIP outliers already on a CII protocol have increased morbidity and mortality, and (4) identify more relevant benchmarks that can be used to determine glycemic control in patients undergoing cardiac surgery.
METHODS
This study was approved by the Boston University Medical Center Institutional Review Board (Protocol No. H-25760), and informed consent was obtained from each patient.
Eligibility and Exclusion Criteria
This was an observational, single-center study involving adult patients (both with and without diabetes) undergoing cardiac surgery from January 1, 2008, to August 30, 2011. Patients undergoing coronary artery bypass surgery (CABG), valve repair and replacement, and combinations of CABG plus valve surgery were included. Patients undergoing aneurysm repair with or without deep hypothermic circulatory arrest were excluded.
Glycemic Control Protocols
All patients received a CII (100 units of regular insulin in 100 mL of 0.9% normal saline) to maintain serum glucose between 120 and 180 mg/dL. Infusions were initiated on anesthetic induction and continued during the periods of cardiopulmonary bypass and cardioplegic arrest, after the discontinuation of cardiopulmonary bypass, and for at least 18 hours in the intensive care unit (ICU) as previously described. 13 After the 18-hour ICU period, patients were transitioned off the CII using either short-or longacting insulin agents to maintain a fasting glucose level between 90 and 120 mg/dL and postsupper glucose level of less than 180 mg/dL. Patients were transitioned off CII when they (1) maintained a stable intravenous insulin infusion rate for at least for 4 hours, (2) were extubated and off inotropic agents, and (3) were ready to begin oral, enteral, or parenteral nutrition. Serum glucose was measured every 30 minutes in the operating room and hourly in the ICU during CII. Blood glucose measurements were obtained using arterial catheters and finger sticks and were measured with the use of point-of-care glucose meters. The mean hospital glucose (MHG) measurement represents the average of all glucose values obtained during the hospital stay. Three-day blood glucose (3BG) values consisted of the average of all glucose values obtained from the end of anesthesia through the second POD (72 hours). SCIP glucose values represent the mean 6:00 AM glucose value for patients on POD 1 and POD 2.
Operative Techniques
Standard operative and anesthetic techniques were used in all patients. Myocardial protection was achieved with multidose infusions of antegrade and retrograde cold (4 C) blood (hematocrit ¼ 20%) potassium (28 mEq/ L) cardioplegia supplemented with mild systemic (35 C) and topical (cold saline lavage at 4 C) hypothermia. All vessels with at least a 50% stenosis were bypassed and each patient received at least 1 internal thoracic artery graft.
Outcomes Measured
In addition to parameters of glycemic control, major adverse events were also documented. These included 30-day mortality, the incidence of myocardial infarctions assessed by both enzyme and electrocardiographic changes as previously described, 2 the incidence of cerebrovascular accidents, defined as a persistent neurologic deficit lasting 24 hours or more, the incidence of deep sternal wound infections, defined as any infection reaching or directly involving the sternum, and the incidence of atrial fibrillation that lasted longer than 15 minutes. All patients received postoperative beta-blockers and were continuously monitored on telemetry during their entire postoperative stay. In addition, secondary outcomes that were assessed included time on the ventilator (defined as time of admission to the ICU to the time of extubation), length of ICU stay, and length of hospital stay, all of which were standardized using fast-track protocols. Patients were also assessed for a clinical reason for SCIP ''failure'' by an endocrinologist intimately involved in glycemic control protocols.
Statistical Analyses
Data were summarized using the mean AE standard deviation for continuous variables and the number and percentage for categorical variables using statistical analysis systems (SAS, version 9.0; SAS Institute, Inc, Cary, NC). SCIP compliance was determined prospectively by a hospital committee assigned to track 6:00 AM glucose on POD 1 and POD 2. All glucose levels were adjudicated prospectively in real time for accuracy and validated using retrospectively collected data. Comparison between SCIP compliant subjects and SCIP outliers was performed in bivariate analyses using 2-sample t tests for continuous variables and c 2 or Fisher's exact tests for categorical data. Association of SCIP compliance was assessed with categorical surgical outcomes and continuous glucose outcomes (ie, 3BG) via odds ratios and 95% confident intervals using logistic regression analyses.
RESULTS
The results are summarized in Tables 1 to 3 A logistic regression was used to determine the relationship between BMI and HbA1c. When applied to all subjects and controlling for serum creatinine level, BMI and HbA1c were both independently associated with being an SCIP outlier. However, when we isolated patients with previously diagnosed diabetes mellitus (n ¼ 288), while HbA1c remained significant, BMI was no longer a significant risk factor for failing the SCIP measure in this subgroup. Table 2 lists the reasons for SCIP failure. The most common causes were inadequate transition from CII to subcutaneous insulin (14; 26.5%) and a delay in initiation of the insulin infusion (14; 26.5%). In 13 (25%) patients, no clear cause could be determined. Other factors included an infusion protocol violation (7; 12%), a lapse in glucose monitoring (4; 8%), and failure to transition to a subcutaneous insulin dose once the CII was terminated (3; 2%). Table 3 shows the outcomes of SCIP outliers. SCIP outliers had no significant difference in 30-day mortality, myocardial infarction, permanent strokes, deep sternal wound infections, ventilatory support for more than 24 hours, multisystem failure, or hospital length of stay. The incidence of atrial fibrillation appeared to be less in patients who were SCIP outliers (9, 16.3%, vs 235, 30.3%; P ¼ .05), even after controlling for HbA1c and serum creatinine. Figure 1 , A and B, shows the limitations of SCIP in determining glycemic control. Figure 1 , A, shows the serum glucose values in a patient who is SCIP compliant on PODs 1 and 2. However, as shown in the figure, a significant percentage of these values exceeded both STS and SCIP guidelines throughout the postoperative period. Figure 1 , B, shows glucose values for a patient with type 2 diabetes not compliant with SCIP on POD 2. Nevertheless, this patient maintained both the STS and SCIP guidelines for the remainder of the hospital stay. The limitations of SCIP as a measure of glycemic control are further highlighted in Figure 2 . Glucose levels at 6:00 AM in SCIP outliers on POD 1 decreased to compliant levels on POD 2 (210 AE 5.6 mg/dL vs 137 AE 28 mg/dL; P <.001). Patients who were SCIP outliers on day 2 had compliant glucose levels on day 1 (230 AE 39 mg/dL vs 142 AE 23 mg/dL; P < .001). MHG showed that although SCIP outliers on day 1 had significantly higher glucose levels than SCIP outliers from day 2 and SCIP compliant patients, MHG was consistent with STS and SCIP guidelines (154 AE 61 mg/dL SCIP outliers day 1; P <.001; vs 147 AE 56 mg/dL SCIP outliers day 2, and 144 AE 48 mg/dL SCIP compliant). When early postoperative glycemic control using the 3BG index was assessed (Figure 3 ), SCIP outliers were also consistent with STS and SCIP guidelines, although patients noncompliant with SCIP continued to show higher glucose values (162 AE 19 mg/dL vs 141 AE 6 mg/dL; P <.001).
Overall, 430 or approximately half of the entire cohort had at least 1 glucose value less than 70 mg/dL during the course of their entire hospital stay. There was no difference in the incidence of hypoglycemia between SCIP outlier and SCIP compliant patients. Among the patients who did experience hypoglycemia, this represented only 1.2% of all their hospital glucose values. There was no associated morbidity in any of the patients in whom hypoglycemia developed.
DISCUSSION
Our study has shown that in patients undergoing cardiac surgery and receiving CII to maintain a serum glucose level of less than 180 mg/dL, a certain percentage of patients will be SCIP outliers. Outliers are more likely to have diabetes necessitating insulin, have higher HbA1c levels, and increased BMI. Despite being SCIP outliers, these patients had no increase in postoperative morbidity, mortality, or length of hospital stay. Similar results were found by Murphy and coworkers, 9 who studied the incidence of SCIP compliance in 108 patients undergoing cardiac surgical procedures. Although each patient received CII designed to maintain serum glucose levels between 100 and 140 mg/dL, 10 (9%) patients were found to be SCIP outliers. Glycemic control was assessed by the average blood glucose in the initial 48 hours postoperatively, the duration of hyperglycemia (percentage of time with blood glucose > 200 mg/dL), and the intensity of the implementation of the insulin infusion (defined as the number of blood glucose checks per hour on the insulin infusion). The average mean blood glucose between the SCIP compliant patients and outliers was 148 AE 2 versus 203 AE 10 mg/dL (P<.0001). However, the postoperative percentage of time that was spent with a blood glucose level of more than 200 mg/dL was higher in SCIP compliant patients (14% AE 0.2% vs 0.48% AE 4%; P<.0001). The number of glucose checks per hour tended to be higher in the noncompliant group, indicating that SCIP noncompliance was not due to less intense implementation of the insulin infusion protocol. Murphy and coworkers 9 concluded that even the use of CII targeted to a blood glucose of less than 140 mg/dL did not guarantee compliance with SCIP even though more frequent adjustments were made in the SCIP outlier group. Stulberg and coworkers 10 sought to examine the relationship between SCIP adherence and postoperative infection rates in a retrospective study using the Premier Prospective database. This involved 398 hospitals and 405,720 patients. The incidence of surgical infections was 1.1% in SCIP compliant patients versus 1.5% in noncompliant patients. The authors were not able to demonstrate a relationship between SCIP adherence and a decreased incidence of infections. This is in agreement with other studies that have failed to validate the effectiveness of SCIP in reducing infection rates.
11,12
It is not surprising that the 2 isolated SCIP glucose measurements do not predict postoperative outcomes. Studies have shown that metrics that incorporate glucose values over longer time periods are prognostically superior to data from just the first 24 or 48 hours of a patient's hospitalization. Furnary, Wu, and Bookin 14 assessed the efficacy of glycemic control using 3BG in 1980 patients undergoing cardiac surgery using CII. This was calculated from an average of all glucose values on the day of surgery and the first and second PODs. An increase in 3BG was an independent predictor of postoperative mortality (P<.001). Changes in 3BG were also predictive of deep sternal wound infections, longer hospital lengths of stay, the need for blood transfusions, new-onset atrial fibrillation, and low cardiac output syndrome. Kosiborod and coworkers 15 also sought to determine which metrics of glycemic control would best predict hospital mortality in patients admitted with an acute myocardial infarction. In this study, 3 parameters of glycemic control were compared with a single admission glucose value in the ability to predict hospital mortality. MHG was the average of each patient's glucose value during the hospitalization. A time-averaged glucose value was the area under the curve of all glucose values during a specified time period divided by the length of the time period. The hyperglycemic index was the area under the curve of hyperglycemic glucose values over a particular time period. 16 Each of these methods was evaluated over the first 24 hours, 48 hours, and for the entire hospitalization, and they were better predictors of hospital mortality than a single admission glucose level. MHG over the entire hospital stay was found to be the easiest and most practical parameter to assess glycemic control and its relationship to hospital survival. The authors concluded that metrics that incorporated glucose values over longer time periods were prognostically superior to a single glucose value or data obtained from just the first 24 or 48 hours of a patient's hospitalization after an acute myocardial infarction.
Achieving glycemic control in the perioperative period requires a multidisciplinary approach that includes representatives from nursing, anesthesiology, pharmacy, surgery, and endocrinology. At our own institution, we formed a Perioperative Glycemic Control Committee to help meet SCIP guidelines. A representative from this committee receives SCIP outcome data on a monthly basis and reviews each case that does not meet the glycemic target. Committee members then provide direct feedback to the individual disciplines to make necessary adjustments or identify areas of deficiencies.
Our study is limited in that it was retrospective and we were not able to assess in real time the causes for SCIP failure. Although we did review in detail the hospital records for all patients with SCIP failure, we may not have been able to account for any undocumented changes in clinical conditions that may have also been responsible for SCIP outliers.
Our own data corroborate the findings of these studies that have shown that isolated serum blood glucose values do not accurately predict patient outcomes and do not adequately represent glycemic control during the hospital stay. Therefore, failure to meet SCIP glucose guidelines should not imply substandard care for these patients having cardiac operations. Adherence to SCIP glycemic values is only 1 aspect of effective patient care. Morbidity and mortality in patients undergoing cardiac surgery are likely to be influenced by other factors independent of glycemic control. Hence, SCIP benchmarks for glycemic control should not be the only metric for reporting operative outcomes and determination of hospital monetary reimbursements.
Discussion
Dr Anthony P. Furnary (Portland, Ore). Dr McDonnell, thank you for a beautiful and very concise presentation. We can all be frustrated by this SCIP measure. I think all in this room can agree that the SCIP benchmarks that have been put forth are really scientifically unfounded, and, as you have said, inaccurate. To me, they make little sense. As you have shown, being an outlier at 6:00 AM on the first or second day really has nothing at all to do with the glycemic state of the patient in the first 3 days.
Just as the SCIP glycemic benchmarks have nothing to do with glycemic state, I think it is important to note that tight glycemic control has nothing to do with cardiac surgery outcomes in patients who do not have diabetes. This is a really important point. I want to repeat it. There has not been a single study showing that tight glycemic control alters cardiac surgery outcomes in patients who do not have diabetes. The only outcomes benefits that have ever been shown are in patients who have diabetes or in surgery patients who are receiving total parenteral nutrition for more than 5 days.
A lot of authors have missed that important caveat. It is important because it comes as no surprise, then, that any study that combines both patients with diabetes and those without diabetes in its study population and looks at glycemia-related outcome end points will find that those glycemia-related outcomes are preordained to be what everybody now calls ''noninferior.'' Thus it does not matter whether you look at target blood glucose level, moderate versus tight glucose control, or a glycemic SCIP measure or you look at actual achieved 3BG; you will always end up with a noninferior outcome.
Furthermore, in patients with diabetes, the achieved blood glucose levels are always either at the upper end of the target blood glucose range or, more frequently above that target range. If you wanted to get 100% compliance within a target, say you wanted to be 100% less than 180 mg/dL, then you would have to target 150 mg/dL to get everybody there, to less than 180 mg/dL. I have 3 questions.
First, did you get a chance to analyze the outcomes of just your diabetes subset of patients with regard to 3BG and SCIP compliance?
Dr McDonnell. Thank you very much, Dr Furnary, for that excellent summary. I agree with the majority of your points. You are absolutely right that the majority of the available prospective data in group of patients who are newly revascularized supports the concept that glycemic control reduces the excess risk seen in patients with diabetes having CABG surgery. Not all data are consistent with this benefit being unique to patients with diabetes, however, and subgroup analyses of larger studies suggest CABG patients without diabetes may benefit substantially from postoperative intensive insulin therapy.
I did look at the diabetes CABG subset. This represented 28% of the entire cohort, so it was a small subset. Just of note, 75% of the operations in this data set were CABG and 37% of the total group had a prior diagnosis of diabetes.
We found that 3BG was almost the same between the patients with diabetes and those without diabetes, 148 mg/dL versus 135 mg/dL, respectively, reflecting that all patients receive the same glycemic care perioperatively. We did not see a difference in outcomes between these groups, presumably for 2 reasons: (1) the glucose difference was minimal; (2) the event rate was low, as would be expected in a group of this size in many centers. Our previous speaker noted that the mortality reduction seen over the past 10 or 15 years in cardiac surgery is profound depending on the data set you look at, and it is now difficult to show a difference in outcomes owing to any single intervention, certainly in mortality.
Dr Furnary. As you know, we have developed the 3BG because it covers every component of glycemia-related risk throughout the postoperative period. SCIP decided not to use 3BG or not to use any composite outcome for several reasons: (1) a composite outcome is difficult to collect; (2) it is complex to collect; and (3) it is costly to collect. What would your recommendation be to SCIP? Furthermore, what is your recommendation for the STS in regard to glycemic metrics for patients having cardiac surgery? It is my opinion that the STS really ought to be in charge of this and define a glycemia-related metric for all patients requiring cardiac surgery-and use one that makes scientific sense. What should we collect in the STS database and what should we tell SCIP that they ought to collect for some sensible scientifically related composite glucose measurement?
Dr McDonnell. Thank you for your question. First of all, I am pleased to be part of this conversation, because I think that it is not an easy answer and we need to discuss it across all involved disciplines. I would be happy, as would many of my colleagues, with a measurement that involved more than 1 or 2 measurements to arrive at a true mean and specifically avoid isolated measurements, which are not valid as tools to assess overall glycemic control. As an endocrinologist, I find it concerning that we are using isolated measurements to judge the glycemic care of our patients having cardiothoracic surgery. SCIP could potentially calculate 3BG on a subset of patients randomly selected and report that in the form of an audit, or we could collect 4 to 8 measurements over the course of 2 to 3 days. The SCIP monitors may have difficulty with these more complex measures inasmuch as it would increase time required to collect data, and that would come at a cost. However, the conversation needs to continue, and, I agree, STS needs to be in the forefront. Dr Furnary. Last question: We know that 75% of the SCIP ''violations'' (I call them violations) were caused by a delayed start, poor transition from intravenous to subcutaneous, or some other protocol violation, and the remaining ones were caused just because they were on the protocol and were in that group of patients who end up higher than the protocol target. We also know that the actual achieved glucose is often higher than the target. Shouldn't we therefore just all lower our upper target range and to say 150 mg/dL and keep all our patients on insulin drip protocols for 3 days instead of just 18 hours? That way, all of the glycemia-related risks are fully covered. This is what we have done in Portland, and we end up having 100% SCIP compliance on this glycemic measure, so it is not so frustrating anymore. We just forget about the SCIP thing, because it always works. Dr McDonnell. I will be frank that it took us time, but we have found that many of the elements related to SCIP failure that I noted are remediable. We have remediated many of them in the past 1 to 2 years so that we are at 100% compliance for most months over the past year. We have been over 95% for 2 years. The goal can be reached in most patients inasmuch as insulin is certainly effective. However, reaching the SCIP goal, as we have shown, does not have significant meaning for the patients. Of importance here is that SCIP compliance should reflect overall glycemic control and not merely an attempt to arrive temporarily at the 6:00 AM target of less than 200 mg/dL, after which control may be abandoned.
What I would also say is that intravenous insulin therapy that is prolonged after cardiothoracic surgery with subcutaneous insulin to cover meals is very elegant and is a beautiful therapy. However, I just do not think it is available to every institution. For many reasons, we decided to master the subcutaneous transition by day 2, and that involved a team of providers, including me and another attending, with fellows, pharmacists sometimes, and also midlevel providers, who can be specifically trained to manage intensive subcutaneous insulin in patients having cardiothoracic surgery. I would say either way it is accomplishable, and whether you are doing a prolonged insulin infusion on the step-down unit or early transition to scheduled subcutaneous insulin, an enormous amount of commitment to both the nurses and to patients is required, and you know that better than anyone else.
Dr Lars G. Svensson (Cleveland, Ohio). Dr McDonnell, congratulations on a very important and timely study. Unfortunately, this is something that we are going to have to deal with increasingly, as you, I am sure, are all too aware. At the moment, there are some 70 patient and outpatient measures that are imposed on institutions, and at the last count I saw, they are going up to about 120. Increasingly, we are going to be playing defense against all these various quality measures, and it certainly is a challenge for those that have to deal with responding to this and observing the quality of our departments.
As you know, the bump-up in sugar after surgery is a normal response to trauma. We all learned that in physiology, and our trauma surgery colleagues have had to deal with the same issue. Unfortunately, getting the SCIP measures changed has been very difficult. As you know, the time interval, which is now measured, will be changing. Fortunately, for those of you who had to deal with the issue of cold patients in the ICU, we managed to convince various people that the SCIP measure for that was completely wrong, that we would be doing patients harm if we rewarm them after surgery to the point that they are normothermic with the pump. So they did respond to that.
In response to the issue of blood sugars, we went through various changes to try to deal with this issue. We noticed that blood sugar levels rose in patients who received vancomycin with a glucose carrier; patients who were sicker, who usually went up to the ICU late in the day or were on epinephrine and also had an increase in their blood sugar levels. So we recommended various things, and our nurses were very helpful. For example, a 10 o'clock glucose value that rises above 160 mg/dL we recheck at 3 o'clock to try to meet this very measure. The danger in this measure aggressively is particularly that the patients could become hypoglycemic.
I have a couple of questions. The categories of complications that you looked at were fairly broad. The ones as a surgeon I would worry about as potentially being a factor with high sugars and diabetes is in the patients with bilateral internal thoracic arteries and the risk of wound infection. We know they have a higher risk. Do you have the numbers to look at that subcategory of patients? Your incidence of multiple organ failure was remarkably good and low, but that may be another place where high sugars may play a role as also with lactic acidosis. Did you look at these subgroups?
My final question concerns talk about a National Institutes of Health study within the cardiothoracic cooperative network looking at this very issue. Is this something that you think should be taken further?
Dr McDonnell. Thank you very much. I echo your sentiment and your comments about the strategies that you have used to improve or to reach the SCIP measure and your concern for the potential to go overboard with targeted insulin therapy to attain a glucose goal, placing patients at risk.
To answer your first question, we do not have the graft type in this data set, specifically the bilateral internal thoracic arteries, but we have discussed this as a variable that may be significant.
Your second question concerned the fact that SCIP is linked to monetary reimbursement and to judging providers and their care. I think it should go to wherever committee or organization it could go to in order to make rationale change. Larger multi-institutional studies are costly, but if they can be used to assess the relevance of several SCIP measures, it may be of value. In my experience and opinion, once a program has made the effort to control glucose and if this can be proven or established by the institution, it is frustrating to have to address the random miss, the random SCIP outlier who is not at increased risk of poor outcomes. Unfortunately, at our institution we continue to have to respond to SCIP reviewers by spending up to an hour per case trying to determine and document why a patient had a glucose elevation for a few hours of their entire stay, which likely has no relevance to their care. Additionally, we are asked how to prevent this from happening, which, as we have shown, is impossible to say for all patients inasmuch as in at least 25% of cases there is no identifiable reason for the hyperglycemic event. This is consistent with the idea that transient physiologic hyperglycemia can be unpredictable after cardiothoracic surgery surgery, which, despite having little to no clinical consequence, currently has significant administrative consequence.
Dr Thomas M. Beaver (Gainesville, Fla). I would caution against totally throwing SCIP out. I believe there is a ''culture effect'' in trying to make things better. I would also remind the audience that glucose is just one of the many SCIP measures, including getting the antibiotics in on time during the time out with the anesthesiologist; stopping the antibiotics; appropriate choice of antibiotics; and warming patients. You can also look at the SCIP overall composite score. What we found at our own institution is that, as we have improved our SCIP composite score, our rate of global class I surgical infections have decreased by 50% across the board.
Have you had a chance to look at your SCIP composite score in this group of patients to determine whether that may have had any effect?
Dr McDonnell. Thank you for your comment. I think that is such an important way to end this session. SCIP is important in the way it improved glycemic control and other evidence-based practice in many institutions. Institutions should be held accountable for their practice of evidence-based care, and this is unquestionable for the sustained achievement of optimal patient outcomes. The priority with SCIP continues to be in line with clinicians, which is to optimize clinical outcomes. What we and others have tried to highlight, however, is that the parameters selected have to be simple to measure as well as evidence-based and at minimum reflective of the actual practice. Otherwise, the SCIP culture becomes a negative force as an unintended consequence.
Regarding the composite measure, it is possible that Dr Lazar knows the answer to this. I do not know whether the composite score for cardiothoracic surgery has been linked to outcomes in our institution. I do know that we have extremely low infection rates, as many hospitals do now, after the institution of many SCIP measures, not just glucose control. But I do not know whether Dr Lazar wants to comment on that.
Dr Lazar. In brief, the answer is no, we have never ever been able to correlate any of the SCIP measures with infection in our institution.
